Skip Navigation
Skip to contents

Journal of Microbiology : Journal of Microbiology

OPEN ACCESS
SEARCH
Search
Advanced Search
mobile menu button

Articles

Page Path
HOME > J. Microbiol > Volume 60(3); 2022 > Article
Review
Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
Jung-ah Choi , Jae-Ouk Kim
Journal of Microbiology 2022;60(3):238-246.
DOI: https://doi.org/10.1007/s12275-022-1547-8
Published online: January 28, 2022
Science Unit, International Vaccine Institute, Seoul 08826, Republic of KoreaScience Unit, International Vaccine Institute, Seoul 08826, Republic of Korea
Corresponding author:  Jae-Ouk Kim , Tel: +82-2-881-1318, 
Received: 20 October 2021   • Revised: 12 December 2021   • Accepted: 15 December 2021
prev next
  • 30 Views
  • 0 Download
  • 9 Web of Science
  • 6 Crossref
  • 6 Scopus
Full Article

Abstract

Middle East Respiratory Syndrome coronavirus (MERS-CoV), a contagious zoonotic virus, causes severe respiratory infection with a case fatality rate of approximately 35% in humans. Intermittent sporadic cases in communities and healthcare facility outbreaks have continued to occur since its first identification in 2012. The World Health Organization has declared MERS-CoV a priority pathogen for worldwide research and vaccine development due to its epidemic potential and the insufficient countermeasures available. The Coalition for Epidemic Preparedness Innovations is supporting vaccine development against emerging diseases, including MERS-CoV, based on platform technologies using DNA, mRNA, viral vector, and protein subunit vaccines. In this paper, we review the usefulness and structure of a spike glycoprotein as a MERSCoV vaccine candidate molecule, and provide an update on the status of MERS-CoV vaccine development. Vaccine candidates based on both DNA and viral vectors coding MERSCoV spike gene have completed early phase clinical trials. A harmonized approach is required to assess the immunogenicity of various candidate vaccine platforms. Platform technologies accelerated COVID-19 vaccine development and can also be applied to developing vaccines against other emerging viral diseases.

  • Cite this Article
    Cite this Article
    export Copy Download
    Close
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies
    J. Microbiol. 2022;60(3):238-246.   Published online January 28, 2022
    DOI: https://doi.org/10.1007/s12275-022-1547-8
    Close
Related articles
Journal of Microbiology : Journal of Microbiology
© The Microbiological Society of Korea.
TOP